Departments of Epidemiology and Oncology, Johns Hopkins Bloomberg School of Public Health and Kimmel Cancer Center, Baltimore, MD, USA.
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Eur J Epidemiol. 2023 Jan;38(1):11-29. doi: 10.1007/s10654-022-00921-1. Epub 2023 Jan 3.
Laboratory and animal research support a protective role for vitamin D in breast carcinogenesis, but epidemiologic studies have been inconclusive. To examine comprehensively the relationship of circulating 25-hydroxyvitamin D [25(OH)D] to subsequent breast cancer incidence, we harmonized and pooled participant-level data from 10 U.S. and 7 European prospective cohorts. Included were 10,484 invasive breast cancer cases and 12,953 matched controls. Median age (interdecile range) was 57 (42-68) years at blood collection and 63 (49-75) years at breast cancer diagnosis. Prediagnostic circulating 25(OH)D was either newly measured using a widely accepted immunoassay and laboratory or, if previously measured by the cohort, calibrated to this assay to permit using a common metric. Study-specific relative risks (RRs) for season-standardized 25(OH)D concentrations were estimated by conditional logistic regression and combined by random-effects models. Circulating 25(OH)D increased from a median of 22.6 nmol/L in consortium-wide decile 1 to 93.2 nmol/L in decile 10. Breast cancer risk in each decile was not statistically significantly different from risk in decile 5 in models adjusted for breast cancer risk factors, and no trend was apparent (P-trend = 0.64). Compared to women with sufficient 25(OH)D based on Institute of Medicine guidelines (50- < 62.5 nmol/L), RRs were not statistically significantly different at either low concentrations (< 20 nmol/L, 3% of controls) or high concentrations (100- < 125 nmol/L, 3% of controls; ≥ 125 nmol/L, 0.7% of controls). RR per 25 nmol/L increase in 25(OH)D was 0.99 [95% confidence intervaI (CI) 0.95-1.03]. Associations remained null across subgroups, including those defined by body mass index, physical activity, latitude, and season of blood collection. Although none of the associations by tumor characteristics reached statistical significance, suggestive inverse associations were seen for distant and triple negative tumors. Circulating 25(OH)D, comparably measured in 17 international cohorts and season-standardized, was not related to subsequent incidence of invasive breast cancer over a broad range in vitamin D status.
实验室和动物研究支持维生素 D 在乳腺癌发生中的保护作用,但流行病学研究尚无定论。为了全面研究循环 25-羟维生素 D [25(OH)D] 与随后发生乳腺癌的关系,我们对来自美国 10 个和欧洲 7 个前瞻性队列的参与者水平数据进行了协调和汇总。共纳入 10484 例浸润性乳腺癌病例和 12953 例匹配对照。采血时的中位年龄(四分位间距)为 57(42-68)岁,乳腺癌诊断时的中位年龄为 63(49-75)岁。采用广泛接受的免疫测定法和实验室检测新测定了预测前循环 25(OH)D,如果是队列中之前测定的,则通过该测定法进行校准,以允许使用通用指标。采用条件逻辑回归估计每个研究的与季节标准化 25(OH)D 浓度相关的相对风险(RR),并通过随机效应模型进行合并。在调整乳腺癌危险因素的模型中,每个百分位的乳腺癌风险与第 5 百分位的风险无统计学差异,且无明显趋势(P 趋势=0.64)。与基于医学研究所指南(50-<62.5 nmol/L)的充足 25(OH)D 相比,RR 在低浓度(<20 nmol/L,对照组的 3%)或高浓度(100-<125 nmol/L,对照组的 3%;≥125 nmol/L,对照组的 0.7%)时均无统计学差异。25(OH)D 每增加 25 nmol/L,RR 为 0.99(95%置信区间 0.95-1.03)。在亚组分析中,包括根据体重指数、体力活动、纬度和采血季节定义的亚组,相关性均为阴性。尽管肿瘤特征的相关性均无统计学意义,但提示远处转移和三阴性肿瘤存在反比关系。在广泛的维生素 D 状态范围内,17 个国际队列中以可比方式测量并进行季节标准化的循环 25(OH)D 与随后发生浸润性乳腺癌的发生率无关。